Stiripentol: In severe myoclonic epilepsy of infancy (Dravet syndrome)

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 993-1001

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOBAZAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; STIRIPENTOL; VALPROIC ACID;

ANOREXIA; APPETITE DISORDER; ARTICLE; ATAXIA; CLINICAL TRIAL; CLONIC SEIZURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DYSTONIA; HUMAN; INSOMNIA; MORBIDITY; MORTALITY; MUSCLE HYPOTONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; TONIC CLONIC SEIZURE; WEIGHT REDUCTION;

ANTICONVULSANTS; CHILD, PRESCHOOL; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPILEPSIES, MYOCLONIC; HUMANS; INFANT; INFANT, NEWBORN; META-ANALYSIS AS TOPIC; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873449938     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0004-3     Document Type: Article

References (44)

1. Morse RP. Dravet syndrome: inroads into understanding epileptic encephalopathies. J Pediatr. 2011;158(3):354-9.
2. Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl. 2):45-8.
3. Guzzetta F. Cognitive and behavioral characteristics of children with Dravet syndrome: an overview. Epilepsia. 2011;52(Suppl. 2):35-8.
4. Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(Suppl. 2):1-6.
5. Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia. 1990;31:397-400.
6. Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 2011;52(Suppl. 2):50-4.
7. Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol. 2011;53(Suppl. 2):16-8.
8. Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome) [in French]. Arch Pediatr. 2002;9(11):1120-7.
9. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508-12.
10. Lortie A, Chiron C, Dumas C, et al. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol. 1997;12(4):253-9.
11. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-54.
12. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356(9242):1638-42.
13. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250-4.
14. Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590-4.
15. Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325-9.
16. Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629-35.
17. Stiripentol Chiron C. Neurotherapeutics. 2007;4(1):123-5.
18. Diacomit® (stiripentol): EU summary of product characteristics. Gentilly: Biocodex, 2007 Jan 4.
19. Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung. 1984;34(2):199-204.
20. Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia. 2006;47(4):704-16.
21. Fisher JL. Interactions between modulators of the GABAA receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2):160-5.
22. Fisher JL. The anticonvulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190-7.
23. Fisher JL. The effects of stiripentol on GABAA receptors. Epilepsia. 2011;52:76-8.
24. Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Epub: Eur J Paediatr Neurol; 2012.
25. Grosenbaugh DK, Mott DD. Stiripentol is active in status epilepticus model [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6-10.
26. Verleye M, Callizot N, Steinschneider R. Neuroprotective potential of stiripentol against oxygen and glucose deprivation or glutamate exposure in cultured rat cortical neurons [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6-10.
27. Cao D, Ohtani H, Ogiwara I, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome. Epilepsia. 2012;53(7):1140-5.
28. Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14(6):654-62.
29. Levy RH, Lin HS, Blehaut HM, et al. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23(11-12):523-33.
30. Levy RH, Loiseau P, Guyot M, et al. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia. 1984;25(4):486-91.
31. Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36(5):661-9.
32. Arends RH, Zhang K, Levy RH, et al. Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect. Epilepsy Res. 1994;18(2):91-6.
33. Shen DD, Levy RH, Savitch JL, et al. Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol. Epilepsy Res. 1992;12(1):29-36.
34. Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490-504.
35. Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56(5):526-36.
36. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia. 1991;32(2):267-74.
37. Giraud C, Treluyer J-M, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608-11.
38. Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993 Mar-Apr; 34 (2):305-11.
39. May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390-7.
40. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618-26.
41. Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343-8.
42. Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362-8.
43. Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54-7.
44. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):72-5.